{"id":22614,"date":"2016-06-21T13:57:00","date_gmt":"2016-06-21T12:57:00","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=22614"},"modified":"2016-06-21T13:57:00","modified_gmt":"2016-06-21T12:57:00","slug":"actualitzacio-en-la-gestio-de-lmpoc-i-lasma","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/","title":{"rendered":"Actualitzaci\u00f3 en la gesti\u00f3 de l&#8217;MPOC i l&#8217;asma"},"content":{"rendered":"<p>La prevalen\u00e7a de l\u2019<b>MPOC<\/b> a l\u2019Estat espanyol \u00e9s del 9,1% i representa <b>la quarta causa de mortalitat del nostre pa\u00eds<\/b>. El fum del tabac n\u2019\u00e9s el principal factor de risc a m\u00e9s d\u2019altres com la pol\u00b7luci\u00f3, els factors gen\u00e8tics i el d\u00e8ficit de l\u2019enzim alfa1-antitripsina. El tractament farmacol\u00f2gic i l\u2019educaci\u00f3 sanit\u00e0ria del pacient amb MPOC s\u00f3n una part essencial per aconseguir l\u2019\u00e8xit de l\u2019evoluci\u00f3. Tanmateix, <b>l\u2019asma \u00e9s una de les malalties cr\u00f2niques m\u00e9s comunes a tot el m\u00f3n amb una afectaci\u00f3 d\u2019aproximadament 300 milions de persones<\/b>. La incid\u00e8ncia, la morbiditat i la mortalitat d\u2019aquesta malaltia han augmentat malgrat el desenvolupament de medicaments nous. En els \u00faltims temps han aparegut <b>novetats terap\u00e8utiques i guies de consens de les societats cient\u00edfiques que han fet replantejar l\u2019estrat\u00e8gia del tractament<\/b>. \u00c9s per aix\u00f2 que \u00e9s convenient fer una actualitzaci\u00f3 de coneixements i una revisi\u00f3 d\u2019aquestes patologies i de la gesti\u00f3 del tractament.<\/p>\n<p><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/06\/actualitzaci\u00f3-MPOC-asma-jornada-2.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\"alignright  wp-image-22622\" alt=\"actualitzaci\u00f3-MPOC-asma-jornada (2)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/06\/actualitzaci\u00f3-MPOC-asma-jornada-2-1024x663.jpg\" width=\"298\" height=\"193\" \/><\/a>Amb l\u2019objectiu de posar-se al dia de les novetats en terap\u00e8utica inhalat\u00f2ria quant a principis actius, combinacions i nous dispositius per a MPOC i asma, saber gestionar el tractament dels pacients amb MPOC i asma des de l\u2019atenci\u00f3 prim\u00e0ria, i identificar els tipus de pacients que acudeixen als serveis de pneumologia i saber quins s\u00f3n els criteris de selecci\u00f3 dels tractaments que es prescriuen amb inhaladors, el COFB va acollir una<strong> jornada d\u2019actualitzaci\u00f3 i reflexi\u00f3 sobre el maneig i tractament dels pacients amb MPOC i asma<\/strong>, una activitat organitzada conjuntament amb la <a href=\"http:\/\/www.scfarmclin.org\/\" target=\"_blank\" rel=\"noopener\">Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC)<\/a> i la <a href=\"http:\/\/www.sefap.org\/\">Sociedad Espa\u00f1ola de Farmac\u00e9uticos de Atenci\u00f3n Primaria (SEFAP).<\/a><\/p>\n<p>L\u2019equip docent va estar format per <b>Esther Pastor<\/b>, farmac\u00e8utica d\u2019atenci\u00f3 prim\u00e0ria del Servei d\u2019Atenci\u00f3 Prim\u00e0ria Vall\u00e8s Oriental (Institut Catal\u00e0 de la Salut), <b>Pere J. Simonet<\/b>, metge de fam\u00edlia de l\u2019EAP Viladecans 2 de l\u2019Institut Catal\u00e0 de la Salut i membre del grup de Malalties respirat\u00f2ries CAMFiC, i <b>Ingrid Solanes,<\/b> pneum\u00f2loga adjunta del Servei de Pneumologia de l\u2019Hospital de la Santa Creu i Sant Pau de Barcelona.<\/p>\n\n<p>Solanes va explicar a la jornada que en les \u00faltimes d\u00e8cades s\u2019ha produ\u00eft <b>un augment progressiu en l\u2019inter\u00e8s en el maneig dels pacients amb MPOC<\/b>, sent en l\u2019actualitat comparable amb el de l\u2019asma, fet que es veu reflectit en la quantitat de novetats terap\u00e8utiques comercialitzades en els \u00faltims sis anys. Pastor va comentar les principals caracter\u00edstiques d\u2019aquestes novetats, tant pels <b>monof\u00e0rmacs <\/b>com per<b> les combinacions<\/b>, i si aporten algun valor afegit o no. A continuaci\u00f3, Simonet i Solanes van donar la seva<b> visi\u00f3 cl\u00ednica del diagn\u00f2stic i maneig d\u2019aquests pacients<\/b> a l\u2019Atenci\u00f3 Prim\u00e0ria i a l\u2019Atenci\u00f3 Especialitzada de Pneumologia.<\/p>\n<div class=\"box shadow\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/06\/actualitzaci\u00f3-MPOC-asma-jornada-4.jpg\"><img decoding=\"async\" class=\" wp-image-22624 alignleft\" alt=\"actualitzaci\u00f3-MPOC-asma-jornada (4)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/06\/actualitzaci\u00f3-MPOC-asma-jornada-4-1024x683.jpg\" width=\"274\" height=\"182\" \/><\/a>&#8220;Com a principal conclusi\u00f3 podem dir que en els pacients amb MPOC les mesures m\u00e9s importants per millorar la superviv\u00e8ncia i qualitat de vida d\u2019aquests pacients \u00e9s realitzar un <b>correcte diagn\u00f2stic com m\u00e9s aviat millor<\/b> (en la malaltia molt avan\u00e7ada i amb molta simptomatologia hi ha poc marge per millorar el pron\u00f2stic) i <b>fomentar l\u2019exercici f\u00edsic i la deshabituaci\u00f3 tab\u00e0quica<\/b>\u201d explica <b>Roser Vall\u00e8s, vocal d\u2019Atenci\u00f3 Prim\u00e0ria del <\/b>COFB i una de les coordinadores de la jornada. \u201cEls tractaments farmacol\u00f2gics no augmenten la superviv\u00e8ncia, nom\u00e9s <b>milloren la simptomatologia<\/b>. Les novetats terap\u00e8utiques no han demostrat superioritat als f\u00e0rmacs inhaladors que ja ten\u00edem disponibles pel maneig tant de l\u2019asma com de la MPOC\u201d.<\/div>\n<p>La jornada tamb\u00e9 va estar coordinada per <b>Tom\u00e0s Casas\u00edn<\/b>, ex vocal d\u2019Hospitals del COF de Barcelona, <b>Esther Amado<\/b>, vocal a Catalunya de la Sociedad Espa\u00f1ola de Farmac\u00e9uticos de Atenci\u00f3n Primaria (SEFAP), i <b>Julio Mart\u00ednez<\/b>, president de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC).<\/p>\n<p><span style=\"color: #888888;\"><strong>Aquesta jornada tamb\u00e9 es va poder seguir en directe mitjan\u00e7ant connexi\u00f3 Webinar (online).<\/strong><\/span><\/p>\n<p align=\"right\"><b>Amb la col\u00b7laboraci\u00f3 de:<\/b><\/p>\n<p align=\"right\"><a href=\"https:\/\/www.boehringer-ingelheim.es\/\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" class=\"alignright size-thumbnail wp-image-21656\" alt=\"logo-boehringeringelheim\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/logo-boehringeringelheim-150x45.jpg\" width=\"150\" height=\"45\" \/><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La prevalen\u00e7a de l\u2019MPOC a l\u2019Estat espanyol \u00e9s del 9,1% i representa la quarta causa de mortalitat del nostre pa\u00eds. El fum del tabac n\u2019\u00e9s el principal factor de risc a m\u00e9s d\u2019altres com la pol\u00b7luci\u00f3, els factors gen\u00e8tics i el d\u00e8ficit de l\u2019enzim alfa1-antitripsina. El tractament farmacol\u00f2gic i l\u2019educaci\u00f3 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":22622,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[211,938,1004],"class_list":["post-22614","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-asma","tag-atencio-primaria","tag-mpoc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Actualitzaci\u00f3 en la gesti\u00f3 de l&#039;MPOC i l&#039;asma - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Actualitzaci\u00f3 en la gesti\u00f3 de l&#039;MPOC i l&#039;asma - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"La prevalen\u00e7a de l\u2019MPOC a l\u2019Estat espanyol \u00e9s del 9,1% i representa la quarta causa de mortalitat del nostre pa\u00eds. El fum del tabac n\u2019\u00e9s el principal factor de risc a m\u00e9s d\u2019altres com la pol\u00b7luci\u00f3, els factors gen\u00e8tics i el d\u00e8ficit de l\u2019enzim alfa1-antitripsina. El tractament farmacol\u00f2gic i l\u2019educaci\u00f3 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-06-21T12:57:00+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Actualitzaci\u00f3 en la gesti\u00f3 de l&#8217;MPOC i l&#8217;asma\",\"datePublished\":\"2016-06-21T12:57:00+00:00\",\"dateModified\":\"2016-06-21T12:57:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/\"},\"wordCount\":709,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"asma\",\"Atenci\u00f3 prim\u00e0ria\",\"MPOC\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/\",\"name\":\"Actualitzaci\u00f3 en la gesti\u00f3 de l'MPOC i l'asma - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2016-06-21T12:57:00+00:00\",\"dateModified\":\"2016-06-21T12:57:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualitzaci\u00f3 en la gesti\u00f3 de l&#8217;MPOC i l&#8217;asma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Actualitzaci\u00f3 en la gesti\u00f3 de l'MPOC i l'asma - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/","og_locale":"ca_ES","og_type":"article","og_title":"Actualitzaci\u00f3 en la gesti\u00f3 de l'MPOC i l'asma - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"La prevalen\u00e7a de l\u2019MPOC a l\u2019Estat espanyol \u00e9s del 9,1% i representa la quarta causa de mortalitat del nostre pa\u00eds. El fum del tabac n\u2019\u00e9s el principal factor de risc a m\u00e9s d\u2019altres com la pol\u00b7luci\u00f3, els factors gen\u00e8tics i el d\u00e8ficit de l\u2019enzim alfa1-antitripsina. El tractament farmacol\u00f2gic i l\u2019educaci\u00f3 [&hellip;]","og_url":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2016-06-21T12:57:00+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"wpAdminCofbOrg","Temps estimat de lectura":"3 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Actualitzaci\u00f3 en la gesti\u00f3 de l&#8217;MPOC i l&#8217;asma","datePublished":"2016-06-21T12:57:00+00:00","dateModified":"2016-06-21T12:57:00+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/"},"wordCount":709,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#primaryimage"},"thumbnailUrl":"","keywords":["asma","Atenci\u00f3 prim\u00e0ria","MPOC"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/","url":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/","name":"Actualitzaci\u00f3 en la gesti\u00f3 de l'MPOC i l'asma - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#primaryimage"},"thumbnailUrl":"","datePublished":"2016-06-21T12:57:00+00:00","dateModified":"2016-06-21T12:57:00+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2016\/06\/21\/actualitzacio-en-la-gestio-de-lmpoc-i-lasma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Actualitzaci\u00f3 en la gesti\u00f3 de l&#8217;MPOC i l&#8217;asma"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"La prevalen\u00e7a de l\u2019MPOC a l\u2019Estat espanyol \u00e9s del 9,1% i representa la quarta causa de mortalitat del nostre pa\u00eds. El fum del tabac n\u2019\u00e9s el principal factor de risc a m\u00e9s d\u2019altres com la pol\u00b7luci\u00f3, els factors gen\u00e8tics i el d\u00e8ficit de l\u2019enzim alfa1-antitripsina. El tractament farmacol\u00f2gic i l\u2019educaci\u00f3 [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/22614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=22614"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/22614\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=22614"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=22614"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=22614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}